Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Update

Seres Therapeutics, Inc. (NASDAQ:MCRB) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 219,815 shares, a drop of 54.1% from the May 31st total of 478,817 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average daily volume of 102,140 shares, the short-interest ratio is currently 2.2 days.

Institutional Investors Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in shares of Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 3,918 shares in the last quarter. 683 Capital Management LLC bought a new stake in shares of Seres Therapeutics during the 4th quarter valued at $778,000. ExodusPoint Capital Management LP purchased a new position in shares of Seres Therapeutics during the 4th quarter valued at $190,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Seres Therapeutics during the 4th quarter valued at $214,000. Finally, Barclays PLC boosted its holdings in Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after buying an additional 6,024 shares during the period. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Stock Performance

NASDAQ:MCRB opened at $7.08 on Monday. The stock has a 50-day simple moving average of $7.36 and a two-hundred day simple moving average of $10.45. The firm has a market capitalization of $68.56 million, a PE ratio of -1.37 and a beta of 0.12. Seres Therapeutics has a 52-week low of $5.31 and a 52-week high of $29.98.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.36 million. Equities analysts forecast that Seres Therapeutics will post -5.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of Seres Therapeutics in a research report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 price target for the company. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen raised shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday, March 13th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.00.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.